Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide ...

E. A. Espiner, M.D., M.R.A.C.P., P. I. Jagger, M.D., J. R. Tucci, M.D., and D. P. Lauler, M.D. In nine separate studies on four patients with severe pitting edema ...

A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...

Currently, patients with HFpEF have high risk of morbidity and mortality, but there is no effective measure for evaluating the prognosis. Studies have found that a variety of ways can lead to the ...

Current treatment options for primary aldosteronism are limited to surgery or mineralocorticoid receptor antagonists when surgery isn't an option. In a phase IIa trial, baxdrostat resolved or reduced ...

Higher serum aldosterone levels among patients with chronic kidney disease (CKD) are independently associated with an increased risk for CKD progression and end-stage kidney disease (ESKD) regardless ...

In a phase 2 trial, an investigational drug that inhibits aldosterone synthase significantly lowered albuminuria in patients with or without type 2 diabetes. PHILADELPHIA—A novel selective aldosterone ...

Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat, an aldosterone synthase inhibitor, significantly decreased automated office systolic BP ...

An investigational antihypertensive agent that inhibits the enzyme involved in aldosterone production, called MLS-101, significantly reduces blood pressure in patients with uncontrolled and resistant ...

Please provide your email address to receive an email when new articles are posted on . Aldosterone is associated with an increased risk of chronic kidney disease progression and the development of ...